Michelle L. Basil - May 18, 2021 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
EVP and General Counsel
Signature
/s/ Thomas V. Powers, attorney-in-fact for Ms. Basil
Stock symbol
HAE
Transactions as of
May 18, 2021
Transactions value $
-$12,142
Form type
4
Date filed
5/20/2021, 06:02 PM
Previous filing
May 18, 2021
Next filing
Jun 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Award +6.19K +40.17% 21.6K May 18, 2021 Direct F1, F2, F3
transaction HAE Common Stock Award +17.7K +81.88% 39.3K May 18, 2021 Direct F2, F3, F4
transaction HAE Common Stock Sale -$12.1K -220 -0.56% $55.19 39K May 19, 2021 Direct F3, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Award $0 +16.7K $0.00 16.7K May 18, 2021 Common Stock 16.7K $56.57 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3 This number includes unvested RSUs previously reported.
F4 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.
F5 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F6 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.